What is the future of drug discovery


Consortium aims to promote the development of new active ingredients

In April 2018, the European Commission awarded the EU-OPENSCREEN consortium the coveted status of European Research Infrastructure Consortium (ERIC). On September 25th, the ERIC plaque was presented in a ceremony on the research campus in Berlin-Buch.

The Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin, together with the Max Delbrück Center for Molecular Medicine in Berlin (MDC) and the Helmholtz Center for Infection Research (HZI) in Braunschweig, advanced this consortium. All three institutes are also active partners in the Helmholtz Active Substance Initiative. In addition to FMP, MDC and HZI, the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) is involved as a partner institute in Germany.

The consortium bundles the infrastructures of 20 research institutes from seven European countries so far in order to advance the development of new active ingredients. EU-OPENSCREEN ERIC (www.eu-openscreen.eu) has its headquarters in Germany on the research campus Berlin-Buch. Other founding countries include Norway, the Czech Republic, Latvia, Finland, Poland and Spain. Denmark is initially involved as an observer and from 2019 as a full member. Several other countries are preparing to participate.

EU-OPENSCREEN ERIC is financed by the member states and funded in Germany by the Federal Ministry of Education and Research with around 23 million euros. EU-OPENSCREEN is also well positioned for the future. For the EU Horizon2020 calls for proposals in 2018, all four submitted applications were positively assessed. Among other things, EU-OPENSCREEN will coordinate a Europe-wide project with 33 partners and a volume of five million euros over the next four years.

Further information can be found at https://www.eu-openscreen.eu/

Back to overview